Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
JAMA dermatology, 2020 This randomized clinical trial investigates the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis.
J. Silverberg +10 more
semanticscholar +1 more source
Proderm technology: a water- based lipid delivery system for dermatitis that penetrates viable epidermis and has antibacterial effects. [PDF]
, 2019 BackgroundA defective skin barrier and bacterial colonization are two important factors in maintenance and progression of atopic dermatitis and chronic allergic/irritant hand dermatitis.
Caputo-Janhager, Melinda +4 more
core +3 more sources
British Journal of Dermatology, 2020 Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin‐13, a key driver of atopic dermatitis (AD).
J. Silverberg +11 more
semanticscholar +1 more source
In Memoriam: Dr.a Olívia Bordalo (1951 – 2011)
Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2011 .
An Goossens
doaj +1 more source
Aquarium dermatitis: Cercarial dermatitis in an aquarist [PDF]
, 1998 A 33-year-old man presented with very itchy red papules on the back of his hands and forearms. These papules appeared about 90 min after he had cleaned his aquarium in which he kept native fish and watersnails.
Bastert, J. +3 more
core +1 more source
Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]
, 2020 Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos +9 more
core +3 more sources
Pathophysiology of atopic dermatitis: Clinical implications.
Allergy and Asthma Proceedings, 2019 Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic predisposition, epidermal barrier disruption, and dysregulation of the immune system are some of the critical components of AD.
Jihyun Kim, B. Kim, D. Leung
semanticscholar +1 more source
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
New England Journal of Medicine, 2020 BACKGROUND Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.
K. Kabashima +3 more
semanticscholar +1 more source
Gender differences in depression and anxiety among atopic dermatitis patients
Indian Journal of Dermatology, 2015 Background: Dermatological patients invariably suffer one or the other psychological problems which may escalate to the extent of a mental disorder. One of the most common dermatological disorders is atopic dermatitis (AD), but the literature has limited
Shaily Mina +3 more
doaj +1 more source
Role of serum melatonin and oxidative stress in childhood atopic dermatitis: A prospective study
Indian Dermatology Online Journal, 2020 Background: Many factors have been implicated in the pathogenesis of atopic dermatitis (AD) and recently the role of oxidative damage has been postulated.
Shanthy Devadasan +3 more
doaj +1 more source